Summary of Ocugen, Inc. Q4 2025 Earnings Call

1Key Financial Results and Metrics

Q4 2025 Financials:

Research and Development (R&D) expenses: $10.7 million (up from $8.3 million in Q4 2024).

General and Administrative (G&A) expenses: $6.1 million (down from $6.3 million in Q4 2024).

Net loss per common share: $0.06 (improved from $0.50 in Q4 2024).

Full Year 2025 Financials:

R&D expenses: $39.8 million (up from $32.1 million in 2024).

G&A expenses: $27.6 million (up from $26.7 million in 2024).

Net loss per common share: $0.23 (compared to $0.20 in 2024).

Cash Position: Current cash and cash equivalents extend the runway into 2026, bolstered by a recent $22.5 million capital raise and potential additional funds from warrant exercises.

2Strategic Updates and Business Highlights

Clinical Development:

Enrollment completed for the Phase 3 Limelight trial of OCU400 for retinitis pigmentosa (RP), with top-line data expected in 2027.

Positive long-term data from the Phase 1/2 trial of OCU400 showed sustained visual function improvement.

OCU410ST for Stargardt disease is ahead of schedule, with top-line data anticipated in 2027.

OCU410 for geographic atrophy (GA) in dry AMD demonstrated a 46% reduction in lesion growth in preliminary Phase 2 data.

Partnerships: Secured a regional licensing agreement with QuanDan Pharmaceutical for OCU400 in Korea, enhancing financial stability and market reach.

Leadership Changes: Strengthened executive team with key appointments to support commercialization efforts.

3Forward Guidance and Outlook

2026 Milestones:

Completion of enrollment for OCU410ST.

Full Phase 2 data for OCU410 expected soon.

Initiation of Phase 3 for OCU410 in GA.

Start of rolling BLA submission for OCU400 in the third quarter of 2026.

Long-term Vision: Commitment to file three BLAs over the next three years, positioning Ocugen as a leader in gene therapy for blindness diseases.

4Bad News, Challenges, or Points of Concern

Increased Expenses: R&D expenses are rising, indicating higher investment in clinical trials, which may pressure cash reserves if not balanced by revenue generation.

Competitive Landscape: Potential approvals of competing therapies for Stargardt disease could impact market dynamics and pricing strategies.

Regulatory Risks: The timeline for FDA feedback on the CMC part of the BLA filing remains uncertain, which could delay approval processes.

5Notable Q&A Insights

Confidence in Timelines: Management expressed strong confidence in meeting timelines for data releases and BLA submissions.

Ellipsoid Zone (EZ) Analysis: Discussed as a potential secondary endpoint, with positive reception from clinicians, indicating its relevance in assessing treatment efficacy.

Market Education: Management believes that the introduction of other therapies could help educate the market, potentially benefiting Ocugen's positioning when OCU410ST launches.

Responder Characteristics: No unique characteristics identified for responders in the GA study, suggesting uniformity across patient groups. Overall, Ocugen, Inc. is navigating a transformative period with significant clinical advancements and strategic partnerships, while also facing challenges related to rising costs and competitive pressures in the gene therapy market.